Invitro International PEG
PEG Ratio (Price/Earnings-to-Growth) of Invitro International (IVRO) as of Jul 26, 2026.
Get this data via API
Financial Data API
PEG
0.00
Last updated:
PEG Ratio (Price/Earnings-to-Growth) of Invitro International is 2026 0.00 . PEG Ratio (Price/Earnings-to-Growth) of Invitro International was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Invitro International Stock analysis
What does Invitro International do? Invitro International is a leading company in the development of cell and tissue cultures as well as test systems for the pharmaceutical, cosmetic, and biotechnology industry. The company was founded in 1982 by Dr. George K. J. Uehara, a renowned scientist and specialist in the field of cell culture technology. His aim was to create a reliable alternative to animal testing to meet the industry's need for safe and effective test systems. Invitro International offers a wide range of products, including cell cultures and tissue samples derived from human or animal tissue. These are of the highest quality and are manufactured under strict quality controls. The tissue cultures are obtained from living organs and are ideal for the development of new drugs and cosmetics, as well as for studying the effects of environmental toxins and chemicals. Another focus of Invitro International is the development of test systems tailored to the needs of customers. These can include in vitro tests on cell and tissue cultures, as well as molecular analysis and screening methods. The company is divided into various industries and sectors, including pharmaceutical research, toxicology, cosmetics industry, biotechnology, and environmental research. Each of these sectors is supervised by specialized scientists and experts who have in-depth knowledge and experience in their respective fields. Invitro International places great emphasis on environmentally friendly and ethical standards in the development of new test systems and products. The company is also involved in various initiatives to promote alternatives to animal testing and actively advocates for the protection and welfare of animals. One of Invitro International's most well-known products is the Eye Irritation Test System (EITS), which is widely used in the cosmetics industry. It is a reliable in vitro test that determines the eye irritation potentials of new products based on human tissue. Invitro International has become a leading company in the field of cell culture technology and is now known worldwide for its high-quality products and services. The company takes pride in offering its customers safe, effective, and environmentally friendly test systems and is committed to continuing to develop innovative solutions to meet the industry's requirements. Invitro International is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Invitro International stock
On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Invitro International since 2006 – with annual values, charts, and detailed analysis.
Access this data via the Eulerpool API
Valuation — Invitro International
All Key Metrics — Invitro International
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth